Amyloid deposition, hypometabolism, and longitudinal cognitive decline
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.
Résumé
OBJECTIVE: Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) population, we examined (1) cross-sectional relationships between amyloid deposition, hypometabolism, and cognition, and (2) associations between amyloid and hypometabolism measurements and longitudinal cognitive measurements. METHODS: We examined associations between mean cortical florbetapir uptake, mean (18) F-fluorodeoxyglucose-positron emission tomography (FDG-PET) within a set of predefined regions, and Alzhiemer's Disease Assessment Scale (ADAS-cog) performance in 426 ADNI participants (126 normal, 162 early mild cognitive impairment [EMCI], 85 late MCI [LMCI], 53 Alzheimer disease [AD] patients). For a subset of these (76 normal, 81 LMCI) we determined whether florbetapir and FDG-PET were associated with retrospective decline in longitudinal ADAS-cog measurements. RESULTS: Twenty-nine percent of normal subjects, 43% of EMCI patients, 62% of LMCI patients, and 77% of AD patients were categorized as florbetapir positive. Florbetapir was negatively associated with concurrent FDG and ADAS-cog in both MCI groups. In longitudinal analyses, florbetapir-positive subjects in both normal and LMCI groups had greater ongoing ADAS-cog decline than those who were florbetapir negative. However, in normal subjects, florbetapir positivity was associated with greater ADAS-cog decline than FDG, whereas in LMCI, FDG positivity was associated with greater decline than florbetapir. INTERPRETATION: Although both hypometabolism and β-amyloid (Aβ) deposition are detectable in normal subjects and all diagnostic groups, Aβ showed greater associations with cognitive decline in normal participants. In view of the minimal cognitive deterioration overall in this group, this suggests that amyloid deposition has an early and subclinical impact on cognition that precedes metabolic changes. At moderate and later stages of disease (LMCI/AD), hypometabolism becomes more pronounced and more closely linked to ongoing cognitive decline.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Annals of Neurology
- Thématique
- Dementia and Cognitive Impairment Research
- Domaine
- Medicine
- Établissements canadiens
- —
- Organismes subventionnaires
- National Institute on AgingAvid RadiopharmaceuticalsUniversity of California, San DiegoNational Institute of Biomedical Imaging and BioengineeringCanadian Institutes of Health ResearchUniversity of California, Los AngelesNational Institutes of HealthServierElanAstellas PharmaEisaiGenentechUniversity of OxfordNorthern California Institute for Research and EducationPfizerBiogenBioClinicaAlzheimer's AssociationAmorfix Life SciencesDana FoundationBayer HealthCareAlzheimer's Disease Neuroimaging InitiativeMeso Scale DiagnosticsF. Hoffmann-La RocheMedpaceAstraZenecaEli Lilly and CompanyBristol-Myers SquibbNovartis Pharmaceuticals CorporationAmgenSynarcFoundation for the National Institutes of Health
- Mots-clés
- Cognitive declineNeuroimagingPositron emission tomographyCognitionInternal medicineSubclinical infectionAlzheimer's diseaseCogPsychologyMedicineLongitudinal studyFluorodeoxyglucoseDementiaDiseaseEndocrinologyPathologyNeuroscience
- Résumé présent dans OpenAlex
- oui